Ally Bridge Group NY LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 52.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 160,000 shares of the company’s stock after acquiring an additional 55,000 shares during the quarter. Guardant Health comprises about 7.9% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 3rd largest position. Ally Bridge Group NY LLC’s holdings in Guardant Health were worth $10,598,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in GH. Capital Research Global Investors lifted its stake in Guardant Health by 50.0% in the fourth quarter. Capital Research Global Investors now owns 7,927,702 shares of the company’s stock valued at $792,929,000 after buying an additional 2,640,910 shares during the period. Capital International Investors lifted its stake in Guardant Health by 38.0% in the fourth quarter. Capital International Investors now owns 2,971,384 shares of the company’s stock valued at $297,198,000 after buying an additional 818,309 shares during the period. Casdin Capital LLC acquired a new position in Guardant Health in the fourth quarter valued at about $79,016,000. D1 Capital Partners L.P. acquired a new position in Guardant Health in the fourth quarter valued at about $47,867,000. Finally, Iron Triangle Partners LP increased its holdings in shares of Guardant Health by 131.7% in the fourth quarter. Iron Triangle Partners LP now owns 440,255 shares of the company’s stock worth $44,034,000 after acquiring an additional 250,255 shares in the last quarter. Institutional investors and hedge funds own 89.36% of the company’s stock.
Analyst Ratings Changes
Several brokerages have issued reports on GH. The Goldman Sachs Group lowered their price target on Guardant Health from $90.00 to $80.00 and set a “buy” rating for the company in a report on Monday, August 8th. Credit Suisse Group began coverage on Guardant Health in a report on Wednesday, August 24th. They issued an “outperform” rating and a $80.00 price target for the company. OTR Global downgraded Guardant Health to a “positive” rating in a report on Monday, August 1st. Piper Sandler began coverage on Guardant Health in a report on Thursday, June 2nd. They issued an “overweight” rating and a $65.00 price target for the company. Finally, Morgan Stanley lowered their price target on Guardant Health from $85.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 8th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $115.75.
Insider Activity at Guardant Health
Guardant Health Stock Performance
Shares of NASDAQ GH opened at $59.28 on Friday. The stock has a 50 day moving average price of $50.42 and a 200 day moving average price of $51.83. Guardant Health, Inc. has a 52 week low of $27.65 and a 52 week high of $132.87. The company has a debt-to-equity ratio of 3.56, a quick ratio of 5.83 and a current ratio of 6.18. The stock has a market capitalization of $6.06 billion, a PE ratio of -10.96 and a beta of 0.80.
Guardant Health (NASDAQ:GH – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($2.25) EPS for the quarter, missing the consensus estimate of ($1.25) by ($1.00). Guardant Health had a negative net margin of 135.03% and a negative return on equity of 99.90%. The company had revenue of $109.14 million for the quarter, compared to analyst estimates of $105.14 million. During the same period last year, the company posted ($0.96) earnings per share. The business’s revenue for the quarter was up 18.5% on a year-over-year basis. Analysts predict that Guardant Health, Inc. will post -6.12 earnings per share for the current fiscal year.
Guardant Health Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.